144 related articles for article (PubMed ID: 37157905)
21. Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from Germany.
Wilde AB; Lieb C; Leicht E; Greverath LM; Steinhagen LM; Wald de Chamorro N; Petersen J; Hofmann WP; Hinrichsen H; Heyne R; Berg T; Naumann U; Schwenzer J; Vermehren J; Geier A; Tacke F; Müller T
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33806503
[TBL] [Abstract][Full Text] [Related]
22. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
[TBL] [Abstract][Full Text] [Related]
23. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.
Gómez E; Montero JL; Molina E; García-Buey L; Casado M; Fuentes J; Simón MA; Díaz-González A; Jorquera F; Morillas RM; Presa J; Berenguer M; Conde MI; Olveira A; Macedo G; Garrido I; Hernández-Guerra M; Olivas I; Rodríguez-Tajes S; Londoño M; Sousa JM; Ampuero J; Romero-González E; González-Padilla S; Escudero-García D; Carvalho A; Santos A; Gutiérrez ML; Pérez-Fernández E; Aburruza L; Uriz J; Gomes D; Santos L; Martínez-González J; Albillos A; Fernández-Rodríguez CM
Aliment Pharmacol Ther; 2024 Jun; 59(12):1604-1615. PubMed ID: 38690746
[TBL] [Abstract][Full Text] [Related]
25. Excellent outcome in patients with primary biliary cholangitis in Northwest Italy followed up for up to 30 years.
Rigamonti C; De Benedittis C; Labanca S; Vanni E; Morgando A; Manfredi GF; Azzolina D; Cittone MG; Giannini EG; Saracco GM; Pirisi M
Eur J Gastroenterol Hepatol; 2023 Aug; 35(8):899-906. PubMed ID: 37395243
[TBL] [Abstract][Full Text] [Related]
26. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
27. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
Joshi S; Cauch-Dudek K; Wanless IR; Lindor KD; Jorgensen R; Batts K; Heathcote EJ
Hepatology; 2002 Feb; 35(2):409-13. PubMed ID: 11826416
[TBL] [Abstract][Full Text] [Related]
28. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
[No Abstract] [Full Text] [Related]
29. Decreased infiltration of CD4
Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
[TBL] [Abstract][Full Text] [Related]
30. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
Qian JD; Yao TT; Wang Y; Wang GQ
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
[TBL] [Abstract][Full Text] [Related]
31. Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.
Wang L; Sun K; Tian A; Liu Y; Zhang M; Zhou X; Han Y
Minerva Med; 2022 Dec; 113(6):974-982. PubMed ID: 33949176
[TBL] [Abstract][Full Text] [Related]
32. Real-world experience with obeticholic acid in patients with primary biliary cholangitis.
D'Amato D; De Vincentis A; Malinverno F; Viganò M; Alvaro D; Pompili M; Picciotto A; Palitti VP; Russello M; Storato S; Pigozzi MG; Calvaruso V; De Gasperi E; Lleo A; Castellaneta A; Pellicelli A; Cazzagon N; Floreani A; Muratori L; Fagiuoli S; Niro GA; Feletti V; Cozzolongo R; Terreni N; Marzioni M; Pellicano R; Pozzoni P; Baiocchi L; Chessa L; Rosina F; Bertino G; Vinci M; Morgando A; Vanni E; Scifo G; Sacco R; D'Antò M; Bellia V; Boldizzoni R; Casella S; Omazzi B; Poggi G; Cristoferi L; Gerussi A; Ronca V; Venere R; Ponziani F; Cannavò M; Mussetto A; Fontana R; Losito F; Frazzetto E; Distefano M; Colapietro F; Labanca S; Marconi G; Grassi G; Galati G; O'Donnell SE; Mancuso C; Mulinacci G; Palermo A; Claar E; Izzi A; Picardi A; Invernizzi P; Carbone M; Vespasiani-Gentilucci U;
JHEP Rep; 2021 Apr; 3(2):100248. PubMed ID: 33681748
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.
van Hoogstraten HJ; Hansen BE; van Buuren HR; ten Kate FJ; van Berge-Henegouwen GP; Schalm SW
J Hepatol; 1999 Aug; 31(2):256-62. PubMed ID: 10453938
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.
Duan W; Ou X; Wang X; Wang Y; Zhao X; Wang Q; Wu X; Zhang W; Ma H; You H; Jia J
Rev Esp Enferm Dig; 2018 Sep; 110(9):557-563. PubMed ID: 29739227
[TBL] [Abstract][Full Text] [Related]
35. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
36. Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients.
Lammert C; Juran BD; Schlicht E; Chan LL; Atkinson EJ; de Andrade M; Lazaridis KN
J Gastroenterol; 2014 Oct; 49(10):1414-20. PubMed ID: 24317935
[TBL] [Abstract][Full Text] [Related]
37. How the concept of biochemical response influenced the management of primary biliary cholangitis over time.
Lammers WJ; Leeman M; Ponsioen CI; Boonstra K; van Erpecum KJ; Wolfhagen FH; Kuyvenhoven JP; Vrolijk JM; Drenth JP; Witteman EM; van Nieuwkerk CM; van der Spek BW; Witteman BJ; Erkelens GW; Verhagen MA; van Tuyl SA; Poen AC; Brouwer JT; Ter Borg F; Koek GH; van Ditzhuijsen TJ; Hansen BE;
Neth J Med; 2016 Jul; 74(6):240-6. PubMed ID: 27571721
[TBL] [Abstract][Full Text] [Related]
38. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines.
Terziroli Beretta-Piccoli B; Stirnimann G; Mertens J; Semela D; Zen Y; Mazzucchelli L; Voreck A; Kolbus N; Merlo E; Di Bartolomeo C; Messina P; Cerny A; Costantini S; Vergani D; Mieli-Vergani G;
J Autoimmun; 2021 Jan; 116():102578. PubMed ID: 33229138
[TBL] [Abstract][Full Text] [Related]
39. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.
Hao YL; Bian ZL; Ju LL; Liu Y; Qin G
Dig Dis Sci; 2020 Feb; 65(2):470-479. PubMed ID: 31377883
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Ding D; Guo G; Liu Y; Zheng L; Jia G; Deng J; Sun R; Wang X; Guo C; Shang Y; Han Y
Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
